格拉泰咪尔治疗复发-缓解型多发性硬化

Glatiramer treatment in relapsing-remitting multiple sclerosis

格拉泰咪尔(GA)是合成的多肽化合物,其通过非特异性免疫调节作用、中枢神经内的旁观者抑制作用、作用于CD4^+CD25^+和CD8^+的调节性T细胞以及促进神经营养因子释放等机制调节免疫网络,使多发性硬化(MS)趋于缓解和修复。临床试验发现在复发缓解型MS(RRMS),GA治疗可减少临床复发、MRI所见的亚临床复发和延缓进展。其安全性好,长期治疗的疗效稳定。在RRMS治疗中一些作用机制优于干扰素,且临床研究发现的确在一些方面优于干扰素。基于这些,GA成为RRMS的一线治疗药物。

Glatiramer acetate （GA） is a synthetic polypeptide prompting the resolution and repair of multiple sclerosis （MS） by unspecific immune-suppression, bystander immune-suppression in CNS, promotion of CD4^＋CD25^＋ and CD8^＋ up-regulation on T cells and neurotrophic factors. Clinical trials of GA in relapsing-remitting MS （RRMS） confirmed the efficacy of GA in reducing relapses （clinical and subclinical detected through MRI） and delaying the progression with good safety profile and long term satble therapeutic effect. In the treatment of RRMS, some mechanisms of GA are superior to those of interferon, with already confirmed observational studies. Based on these, GA has become the first-line therapy for RRMS.